Immunologic Response to Influenza Vaccination in Children and Adolescents

PHASE4CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

September 13, 2018

Primary Completion Date

December 13, 2018

Study Completion Date

December 13, 2018

Conditions
Influenza, HumanImmune Response
Interventions
BIOLOGICAL

Flucelvax inactivated influenza vaccine

Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)

BIOLOGICAL

Fluzone inactivated influenza vaccine

Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)

Trial Locations (2)

15213

General Academic Pediatrics, Pittsburgh

15260

University of Pittsburgh Department of Family Medicine, Pittsburgh

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Richard Zimmerman MD

OTHER

NCT03614975 - Immunologic Response to Influenza Vaccination in Children and Adolescents | Biotech Hunter | Biotech Hunter